Qamar A, et al. - In this analysis of the FOURIER trial data, researchers assessed the interindividual variability in low-density lipoprotein cholesterol (LDL-C) level reduction with the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor drug evolocumab. Study participants included 21,768 patients in the final analysis. With evolocumab treatment, researchers noted an attenuation in LDL-C levels by ≥ 50% in 90.5% of patients and by ≥ 30% in 99.8% of patients with placebo-adjusted analyses. Overall, evolocumab appeared to cause a highly consistent robust reduction in LDL-C levels.